Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)
In this dose-finding trial for PTX in preterm neonates, our findings reveal no discernible clinical advantage associated with either increasing or decreasing the PTX dosage. The relatively high variability in sepsis severity and patients' post-natal ages increase the uncertainty of our findings, but the standardly used dosage of 30 mg/kg/day (5 mg/kg/h for 6 h) has consistently demonstrated safe tolerability without any reported severe adverse events.
Authors
- Jan L Mazela (ORCID: https://orcid.org/0000-0001-9845-6759)
- Irwin Reiss (ORCID: https://orcid.org/0000-0002-9474-6895)
- Robert B. Flint (ORCID: https://orcid.org/0000-0002-3658-594X)
- Şerife Kurul
- Ryszard Lauterbach (ORCID: https://orcid.org/0000-0003-1431-6252)
- Sinno H. P. Simons (ORCID: https://orcid.org/0000-0001-5219-5696)
- H. Rob Taal
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
Institutions
- Poznan University of Medical Sciences (PL)
- Jagiellonian University (PL)
- Erasmus MC (NL)
- KU Leuven (BE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1002/bcp.70334
- Primary Topic
- Neonatal and Maternal Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ZonMw